<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Viltolarsen: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Viltolarsen: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Viltolarsen: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="129261" href="/d/html/129261.html" rel="external">see "Viltolarsen: Drug information"</a> and <a class="drug drug_patient" data-topicid="129305" href="/d/html/129305.html" rel="external">see "Viltolarsen: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F54756234"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Viltepso</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F54741505"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antisense Oligonucleotide</span></li></ul></div>
<div class="block dop drugH1Div" id="F54750991"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4cc06b31-bbc9-4530-9118-12d395c83705">Duchenne muscular dystrophy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Duchenne muscular dystrophy (DMD):</b> Children and Adolescents: IV: 80 mg/kg/dose once weekly. <b>Note:</b> DMD primarily affects males, and rarely females; therefore, clinical trial experience is limited to the male population.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F54750992"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Viltolarsen is mainly excreted unchanged in the urine and renal impairment may increase exposure. However, creatinine is not a reliable measurement of kidney function due to the reduced skeletal mass in patients with Duchenne muscular dystrophy (DMD) so no specific dosage adjustment can be recommended based on eGFR; closely monitor patients with known renal impairment.</p></div>
<div class="block dohp drugH1Div" id="F54750993"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, viltolarsen is not hepatically eliminated.</p></div>
<div class="block doa drugH1Div" id="F54750568"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="129261" href="/d/html/129261.html" rel="external">see "Viltolarsen: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4cc06b31-bbc9-4530-9118-12d395c83705">Duchenne muscular dystrophy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Duchenne muscular dystrophy:</b>
<b>IV:</b> 80 mg/kg once weekly.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F54750570"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); monitor closely.</p></div>
<div class="block doha drugH1Div" id="F54750571"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, viltolarsen is not hepatically eliminated.</p></div>
<div class="block arsc drugH1Div" id="F55460845"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Renal toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Although not observed in clinical trials with viltolarsen, kidney toxicity was observed in animal studies (juvenile mice) at higher than recommended doses. The concern for a potential for renal toxicity with viltolarsen stems from cases of glomerulonephritis, including potentially fatal cases, observed with some antisense oligonucleotides, specifically inotersen. These cases of inotersen-induced glomerulonephritis were accompanied by nephrotic syndrome.</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F54749798"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Reduced ejection fraction (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (13%), diarrhea (13%), vomiting (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bruise (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction (25%; including bruising at injection site, erythema at injection site, swelling at injection site)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (19%), upper respiratory tract infection (63%, including nasopharyngitis, rhinorrhea)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (19%)</p></div>
<div class="block coi drugH1Div" id="F54741210"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block foc drugH1Div" id="F54756235"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Viltepso: 250 mg/5 mL (5 mL)</p></div>
<div class="block geq drugH1Div" id="F54756233"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F54783499"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Viltepso Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg/5 mL (per mL): $338.40</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F54750995"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: Administer by IV infusion over 60 minutes via central or peripheral catheter. Administration should begin as soon as possible after preparation or within 5 hours of preparation; complete infusion within 6 hours of preparation. Do not mix with other medications or infuse other medications concomitantly via the same IV access line. Flush IV access line with NS after infusion. Discard unused portion.</p></div>
<div class="block adm drugH1Div" id="F54750572"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Administer immediately, no more than 5 hours after preparation; complete infusion within 6 hours of preparation. Infuse via peripheral or central venous catheter. Do not mix with other medications or infuse other medications concomitantly via the same IV access line. Administer by IV infusion over 60 minutes. Flush IV access line with NS after infusion. Discard unused portion.</p></div>
<div class="block sts drugH1Div" id="F54750555"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 2°C to 8°C (36°F to 46°F). Do not freeze. If immediate use is not possible, diluted solution may be stored for up to 24 hours at 2°C to 8°C (36°F to 46°F).</p></div>
<div class="block usep drugH1Div" id="F54741481"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping (FDA approved in pediatric patients [age not specified] and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Indication received accelerated approval based on an increase in skeletal muscle dystrophin production in initial trials; continued approval may be contingent upon confirmatory trials.</p></div>
<div class="block cyt drugH1Div" id="F54802954"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F54802951"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F54750551"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Viltolarsen is approved for the treatment of Duchenne muscular dystrophy, a condition that primarily affects males. Animal reproduction studies have not been conducted and females were not included in the original studies (Clemens 2020).</p></div>
<div class="block mopp drugH1Div" id="F54750996"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">GFR using exogenous filtration marker (baseline); urine dipstick (baseline and monthly), serum cystatin C (baseline and every 3 months), urine protein-to-creatinine ratio (baseline and every 3 months). <b>Note:</b> Urine samples should be obtained prior to or ≥48 hours after most recent infusion.</p></div>
<div class="block pha drugH1Div" id="F54750557"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Binds to exon 53 of dystrophin premessenger RNA (mRNA), resulting in exclusion of this exon during mRNA processing. Exon 53 skipping allows for production of an internally truncated dystrophin protein in patients with genetic mutations that are amenable to exon 53 skipping.</p></div>
<div class="block phk drugH1Div" id="F54750558"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 300 mL/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~40%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Metabolically stable; no metabolites detected in plasma or urine.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 100%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 2.5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: ~1 hour.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine: Primarily as unchanged drug.</p></div>
<div class="block phksp drugH1Div" id="F54750566"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Renal impairment is expected to increase exposure.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58216267"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Viltepso</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-32453377">
<a name="32453377"></a>Clemens PR, Rao VK, Connolly AM, et al; CINRG DNHS Investigators. Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial. <i>JAMA Neurol</i>. 2020;77(8):1-10. doi:10.1001/jamaneurol.2020.1264<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/viltolarsen-pediatric-drug-information/abstract-text/32453377/pubmed" id="32453377" target="_blank">32453377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Viltepso.1">
<a name="Viltepso.1"></a>Viltepso (viltolarsen) [prescribing information]. Paramus, NJ: NS Pharma Inc; January 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 129262 Version 32.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
